• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Profusa Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    7/6/26 4:16:24 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care
    Get the next $PFSA alert in real time by email
    false --12-31 0001859807 0001859807 2026-07-02 2026-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION  

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 2, 2026

     

    PROFUSA, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-41177   86-3437271

    (State or Other Jurisdiction of

    Incorporation or Organization)

      (Commission File No.)   (I.R.S. Employer
    Identification No.)

     

    626 Bancroft Way, Suite A

    Berkeley, CA 94710

    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (925) 997-6925

     

    Not Applicable

    (Former name or former address, if changed from last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol (s)   Name of each exchange on which registered
    Common Stock, par value $.0001 per share   PFSA   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 3.03. Material Modifications of Rights of Security Holders.

     

    To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 herein is incorporated by reference into this Item 3.03.

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    At the Profusa, Inc. (the “Company”) annual meeting of stockholders completed on June 23, 2026, the stockholders of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-5 to 1-for-200, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors, or any of its delegated authorized persons, prior to the two-year anniversary of the annual meeting.

     

    Pursuant to such authority granted by the Company’s stockholders, the Company’s board of directors authorized the Company’s Chief Executive Officer to determine the final text of the Amendment, including the reverse stock split ratio, and such other changes as may be required to effectuate the reverse stock split. Accordingly, the Company’s Chief Executive Officer approved a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on July 7, 2026 (the “Effective Time”), and the Company’s common stock will open for trading on The Nasdaq Capital Market on July 7, 2026 on a post-split basis, under the existing ticker symbol “PFSA” but with a new CUSIP number 74319X 306. The Amendment provides that, at the Effective Time, every twenty-five (25) shares of the Company’s issued and outstanding common stock will automatically be combined into one issued and outstanding share of common stock, without any change in par value per share, which will remain $0.0001.

     

    As a result of the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 13.2 million shares to approximately 530 thousand shares, and the number of authorized shares of common stock will remain at 601 million shares. As a result of the Reverse Stock Split, except as set forth below, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock unit awards, performance stock unit awards, and warrants, which will result in a proportional decrease in the number of shares of the Company’s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock unit awards, performance stock unit awards, and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company’s equity incentive plan immediately prior to the Effective Time will be reduced proportionately.

     

    No fractional shares will be issued as a result of the Reverse Stock Split, and instead, the Company will pay cash (without interest or deduction) equal to the fraction of one share to which each stockholder of record would otherwise be entitled, multiplied by the closing price of its common stock on Nasdaq on the date of effectiveness of the Reverse Stock Split. The share amounts set forth in the above paragraph do not take into account any shares which may be paid for in connection with the foregoing treatment of fractional shares.

     

    The summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    1

     

    Item 8.01 Other Events

     

    On July 2, 2026, the Company issued a press release to announce that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five (1:25) reverse stock split of its common stock. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

     

    The tables below set forth the impact of the Reverse Stock Split on the Company’s net loss per common share - basic and diluted and weighted average common shares outstanding - basic and diluted, for the years ended December 31, 2025 and 2024, and the three months ended March 31, 2026 and 2025.

     

    Dollars in thousands except share and per share data

     

       Pre-split(1)   Post-split 
       Year ended December 31,   Year ended December 31, 
       2025   2024   2025   2024 
    Net loss  $(35,823)  $(9,230)  $(35,823)  $(9,230)
    Net loss per common share - basic and diluted  $(107.01)  $(357.14)  $(2,675.35)  $(8,935.14)
    Weighted average common shares outstanding - basic and diluted   334,762    25,844    13,390    1,033 

     

       Pre-split(2)   Post-split 
       Three months ended
    March 31,
       Three months ended
    March 31,
     
       2026   2025   2026   2025 
    Net loss  $(3,456)  $(2,716)  $(3,456)  $(2,716)
    Net loss per common share - basic and diluted  $(2.05)  $(105.09)  $(51.18)  $(2,629.24)
    Weighted average common shares outstanding - basic and diluted   1,688,107    25,844    67,524    1,033 

     

    (1) The pre-split amounts represent amounts from the Company’s Annual Report on Form 10-K, Note 12 for the year ended December 31, 2025.
       
    (2) The pre-split amounts represent amounts from the Company’s Quarterly Report on Form 10-Q, Note 11 for the three months ended March 31, 2026.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Profusa, Inc., filed with the Secretary of State of the State of Delaware.
    99.1   Press Release dated July 2, 2026
    104   Cover page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    July 6, 2026 Profusa, Inc.
         
      By: /s/ Ben Hwang
      Name:  Ben Hwang
      Title: Chief Executive Officer

     

    3

     

    Get the next $PFSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stover Jack E

    4 - Profusa, Inc. (0001859807) (Issuer)

    5/6/26 10:42:51 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Knechtel Fred S.

    4 - Profusa, Inc. (0001859807) (Issuer)

    5/5/26 9:24:50 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Knechtel Fred S. acquired 818,961 shares (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    2/2/26 6:40:58 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profusa Announces 1-for-25 Reverse Stock Split

    BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five (1:25) reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on July 7, 2026, and the Company’s common stock will open for trading on The Nasdaq Global Market on July 7, 2026 on a post-spl

    7/2/26 11:00:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

    BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals presented at the Company’s 2026 Annual Meeting of Shareholders held on June 23, 2026.  The approved proposals included authorization related to the Company's planned acquisition of the PanOmics™ multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion-related matters intended to strengthen the Company's balance sheet, authorization for a reverse stock split if deemed necessary by the Board to support Nasdaq listing compliance efforts, the election of a direc

    6/24/26 8:00:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

    BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform. The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting validation in

    6/12/26 8:00:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    SEC Filings

    View All

    SEC Form 424B3 filed by Profusa Inc.

    424B3 - Profusa, Inc. (0001859807) (Filer)

    7/7/26 8:52:34 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Profusa Inc.

    424B3 - Profusa, Inc. (0001859807) (Filer)

    7/7/26 8:50:12 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Profusa Inc.

    424B3 - Profusa, Inc. (0001859807) (Filer)

    7/7/26 8:43:09 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Leadership Updates

    Live Leadership Updates

    View All

    Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors

    WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu

    5/14/26 8:01:00 AM ET
    $NVAC
    $PFSA
    $QUCY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

    Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont Berkeley, Calif, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces two major leadership additions as of the close of the business combination with NorthView Acquisition Corp (NVAC).  Peter O'Rourke, former Acting U.S. Secretary of Veterans Affair

    8/19/25 8:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Financials

    Live finance-specific insights

    View All

    Profusa Announces Third Quarter Business and Financial Highlights

    Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights. Ben Hwang, Ph.D., Profusa's Chairman and CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time. In the third

    11/19/25 5:44:52 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology